Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers Harold S. Nelson, MDa, Kenneth R. Chapman, FACPb, Stephen D. Pyke, MScc, Malcolm Johnson, PhDc, John N. Pritchard, PhDc Journal of Allergy and Clinical Immunology Volume 112, Issue 1, Pages 29-36 (July 2003) DOI: 10.1067/mai.2003.1558 Copyright © 2003 Mosby, Inc. Terms and Conditions
Fig. 1 A, Difference in change in mean morning PEF (amPEF) over weeks 1 to 12 between ITT results (fixed-effects model). B, Mean change in clinic FEV1 at week 12 (ITT results). Journal of Allergy and Clinical Immunology 2003 112, 29-36DOI: (10.1067/mai.2003.1558) Copyright © 2003 Mosby, Inc. Terms and Conditions
Fig. 2 A, Odds of achieving a greater than 15 L/min improvement in mean morning PEF (amPEF) with combination therapy compared with concurrent therapy (ITT results). B, Odds of achieving a greater than 30 L/min improvement in morning PEF with combination therapy compared with concurrent therapy (ITT results). Journal of Allergy and Clinical Immunology 2003 112, 29-36DOI: (10.1067/mai.2003.1558) Copyright © 2003 Mosby, Inc. Terms and Conditions
Fig. 3 Raman laser analysis of Seretide metered-dose inhaler formulation on stage 4 of an Anderson Cascade Impactor showing particles of fluticasone propionate (green) , salmeterol (red) , and coassociation of both fluticasone propionate and salmeterol (yellow) . Journal of Allergy and Clinical Immunology 2003 112, 29-36DOI: (10.1067/mai.2003.1558) Copyright © 2003 Mosby, Inc. Terms and Conditions